Abstract Search

ea0049gp174 | Pituitary | ECE2017

Efficacy and safety of switching to pasireotide LAR alone or in combination with pegvisomant in acromegaly patients controlled with combination treatment of first-generation somatostatin analogues and weekly pegvisomant (PAPE study): a prospective open-label 48 week study, preliminary results 24 weeks

Muhammad Ammar , van der Lely Aart Jan , Janssen Joop , Neggers Sebastian

Background: Efficacy and safety of combination treatment of pasireotide LAR with pegvisomant (PEGV) has not been studied yet. Switching to Pasireotide LAR in patients previously controlled with long-acting somatostatin analogues (LA-SSAs) and PEGV could reduce the required PEGV dose to normalize serum IGF1 levels, while the effect on glucose metabolism is unknown.Methods: We enrolled 60 acromegaly patients >18 years with acromegaly who had normal IGF...

0 shares

ea0020p556 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Combined treatment for acromegaly with long-acting somatostatin analogues and pegvisomant: long-term safety up to 4.5 years of follow-up in 86 patients

Neggers Sebastian , De Herder Wouter , Janssen Joop , Feelders Richard , Van Der Lely Aart-Jan

Background: We previously reported on the efficacy, safety and Quality of Life of long-acting somatostatin analogs (SSA) and (twice) weekly pegvisomant (PEG-V) in acromegaly and improvement after the addition of PEG-V to long-acting SSA.Objective: To assess the long term safety in a larger group of acromegalic patients over a larger period of time; 29.2 (1.257.4) months (mean (range)).Design: Pegvisomant was added to SSA mono...

0 shares

Endocrine Abstracts

Combined treatment for acromegaly with long-acting somatostatin analogues and pegvisomant: long-term safety up to 4.5 years of follow-up in 86 patients

BiosciAbstracts